U.S. Markets closed

Regulus Therapeutics Inc. (RGLS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.98-0.07 (-6.67%)
At close: 4:00PM EDT

0.98 0.00 (0.00%)
After hours: 4:21PM EDT

People also watch
PTCTCEMPOMEDOVASVSTM
Full screen
Previous Close1.05
Open1.05
Bid0.98 x 200
Ask1.08 x 300
Day's Range0.96 - 1.10
52 Week Range0.86 - 4.25
Volume575,619
Avg. Volume954,257
Market Cap52.12M
Beta2.07
PE Ratio (TTM)-0.64
EPS (TTM)-1.52
Earnings DateJul 31, 2017 - Aug 4, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.54
Trade prices are not sourced from all markets
  • SmarterAnalyst15 days ago

    Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations

    Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a miR-122 inhibitor for the treatment of hepatitis C, RG-125, a miR-103/107 inhibitor for the treatment of non-alcoholic steatohepatitis, and RGLS5040, a miR-27 inhibitor for the treatment for cholestatic disorders. In the wake of the clinical updates, Chardan analyst Madhu Kumar slashed his price target to $5.00 (from $2.50), while reiterating a Buy rating on the stock. To the company’s credit, the analyst points out that the company's lead drug RG-012, a miR-21 inhibitor for the treatment of Alport syndrome, is still on the run and has a “favorable risk-benefit profile." Kumar reminds “The phase II HERA trial is expected to provide renal biopsy data by year end-2017 and interim efficacy data by mid-2018,” and highlights the drug maker’s future is strongly linked to RG-012 performance.

  • TheStreet.com15 days ago

    Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

    After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

  • Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
    PR Newswire15 days ago

    Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer

    LA JOLLA, Calif., June 13, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promotion of Dr. Mark Deeg to Chief Medical Officer. Dr. Deeg joined Regulus in April 2017 as Vice President of Translational Medicine. In his new role, he will lead the Company's clinical development teams in addition to his oversight of translational medicine.